AR023788A1 - Modificacion amorfa de torasemida - Google Patents

Modificacion amorfa de torasemida

Info

Publication number
AR023788A1
AR023788A1 ARP000102019A ARP000102019A AR023788A1 AR 023788 A1 AR023788 A1 AR 023788A1 AR P000102019 A ARP000102019 A AR P000102019A AR P000102019 A ARP000102019 A AR P000102019A AR 023788 A1 AR023788 A1 AR 023788A1
Authority
AR
Argentina
Prior art keywords
torasemida
amorfa
amendment
detorasemide
methyl
Prior art date
Application number
ARP000102019A
Other languages
English (en)
Original Assignee
Pliva D D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva D D filed Critical Pliva D D
Publication of AR023788A1 publication Critical patent/AR023788A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una modificacion de torasemida amorfa, un procedimiento para la preparacion de la misma, su utilizacion como materia prima para la preparacion de sales detorasemida farmacéuticamente aceptables, formas farmacéuticas que contienen esta modificacion detorasemida amorfa como así también, su utilizacion comodiurético. La torasemida es. N-(1-metiletil-aminocarbonil)-4-(3-metil-fenilamino)-3-piridinsulfonamida.
ARP000102019A 2000-03-20 2000-04-28 Modificacion amorfa de torasemida AR023788A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HR20000162A HRP20000162B1 (en) 2000-03-20 2000-03-20 Amorphous torasemide modification

Publications (1)

Publication Number Publication Date
AR023788A1 true AR023788A1 (es) 2002-09-04

Family

ID=10947070

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102019A AR023788A1 (es) 2000-03-20 2000-04-28 Modificacion amorfa de torasemida

Country Status (29)

Country Link
US (1) US6767917B1 (es)
EP (1) EP1272470B1 (es)
JP (1) JP2003528083A (es)
KR (1) KR20020093847A (es)
CN (1) CN1211368C (es)
AR (1) AR023788A1 (es)
AT (1) ATE256662T1 (es)
AU (1) AU2000241348A1 (es)
BG (1) BG107208A (es)
BR (1) BR0017175A (es)
CA (1) CA2401908A1 (es)
CZ (1) CZ20023436A3 (es)
DE (1) DE60007360T2 (es)
EA (1) EA004950B1 (es)
EE (1) EE200200534A (es)
ES (1) ES2213006T3 (es)
GE (1) GEP20043300B (es)
HR (1) HRP20000162B1 (es)
HU (1) HUP0300596A3 (es)
IL (1) IL151801A0 (es)
IS (1) IS6551A (es)
MX (1) MXPA02009210A (es)
NO (1) NO20024464L (es)
PL (1) PL357154A1 (es)
PT (1) PT1272470E (es)
SK (1) SK15092002A3 (es)
WO (1) WO2001070694A1 (es)
YU (1) YU70502A (es)
ZA (1) ZA200208309B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527319A (ja) * 1999-08-11 2003-09-16 テバ ファーマシューティカル インダストリーズ リミティド トルセミド多形体
IN192178B (es) 2001-08-03 2004-03-06 Ranbaxy Lab
JP2007504136A (ja) 2003-08-28 2007-03-01 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化利尿化合物、組成物、ならびに使用方法
EP1855688A4 (en) 2005-02-24 2011-09-14 Nicox Sa NON-STAINED OXIDE DIURETIC COMPOUNDS, COMPOSITIONS AND USE PROCESSES
CN100421662C (zh) * 2005-11-08 2008-10-01 周卓和 托拉塞米分散片及其制备方法和应用
CN104370805B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 托拉塞米化合物
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
GB8816620D0 (en) 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
DK0812320T3 (da) * 1995-02-22 2003-04-14 Aventis Pharma Ltd Amorft piretanid, polymorfe former deraf, fremgangsmåde til fremstilling deraf og deres anvendelse
IN182496B (es) 1996-02-20 1999-04-17 Reddy Research Foundation
HRP980532B1 (en) 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
JP2003527319A (ja) 1999-08-11 2003-09-16 テバ ファーマシューティカル インダストリーズ リミティド トルセミド多形体

Also Published As

Publication number Publication date
NO20024464D0 (no) 2002-09-18
SK15092002A3 (sk) 2003-05-02
CA2401908A1 (en) 2001-09-27
YU70502A (sh) 2006-01-16
US6767917B1 (en) 2004-07-27
ZA200208309B (en) 2003-10-15
BG107208A (en) 2003-07-31
IL151801A0 (en) 2003-04-10
WO2001070694A8 (en) 2002-03-21
JP2003528083A (ja) 2003-09-24
EP1272470B1 (en) 2003-12-17
DE60007360T2 (de) 2004-10-07
HUP0300596A2 (hu) 2003-07-28
EA004950B1 (ru) 2004-10-28
ATE256662T1 (de) 2004-01-15
ES2213006T3 (es) 2004-08-16
KR20020093847A (ko) 2002-12-16
PL357154A1 (en) 2004-07-12
HRP20000162A2 (en) 2001-12-31
CN1452613A (zh) 2003-10-29
BR0017175A (pt) 2002-12-10
DE60007360D1 (de) 2004-01-29
EE200200534A (et) 2004-04-15
HRP20000162B1 (en) 2004-06-30
AU2000241348A1 (en) 2001-10-03
CN1211368C (zh) 2005-07-20
NO20024464L (no) 2002-09-20
WO2001070694A1 (en) 2001-09-27
PT1272470E (pt) 2004-05-31
CZ20023436A3 (cs) 2003-03-12
IS6551A (is) 2002-09-17
GEP20043300B (en) 2004-02-10
EP1272470A1 (en) 2003-01-08
EA200201003A1 (ru) 2003-02-27
HUP0300596A3 (en) 2005-08-29
MXPA02009210A (es) 2004-09-06

Similar Documents

Publication Publication Date Title
EA200400481A1 (ru) Применение флибансерина для лечения половых расстройств
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
PA8539901A1 (es) Novedosa sal de succinato de o-desmetil-venlafaxina
ECSP066365A (es) Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
UY26886A1 (es) Polimorfos de un análogo de epotilona
DOP2002000433A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso
ATE415817T1 (de) Agrochemische formulierungen
DK1641438T3 (da) Fremgangsmåde til fremstilling af den amorfe form af et lægemiddel
AR028313A1 (es) Un procedimiento para la produccion de una composicion desodorante o antitranspirante
ECSP045498A (es) "difenilazetidinonas sustituidas en anillo, metodo para su producción, medicamentos que comprenden estos compuestos y su uso"
CO5011053A1 (es) Procedimiento para la produccion de una forma de dosificacion solida que contiene carvedilol e hidroclorotiazida y formas farmaceuticas obtenidas por dicho procedimiento
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
YU75601A (sh) Postupak za pripremanje modulatora nesteroidnih glukokortikoidnih receptora
BR0114903A (pt) 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
AR023788A1 (es) Modificacion amorfa de torasemida
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
EE200200591A (et) Püridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks ühenditeks
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
AR028840A1 (es) Un polimorfo v de torasemida, un proceso para su preparacion y forma farmaceutica que lo contiene
PE20011080A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
ITMI20000293A0 (it) Derivati del 3,9-diazabiciclo [3.3.1]nonano ad attivita' analgesica
NO20032411L (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens

Legal Events

Date Code Title Description
FB Suspension of granting procedure